直覺手術 (ISRG) 2026 Q1 法說會逐字稿

內容摘要

  1. 摘要
    • Q1 營收年增 23% 至 27.7 億美元,Non-GAAP EPS 年增至 2.50 美元,手術量年增 17%;美國與歐洲表現強勁,亞洲表現分歧
    • 上修 2026 年 da Vinci 手術量成長指引至 13.5%-15.5%(原為 13%-15%);Non-GAAP 毛利率指引上調至 67.5%-68.5%
    • 盤後市場反應未提及,同業對比資訊亦未揭露
  2. 成長動能 & 風險
    • 成長動能:
      • da Vinci 5、Ion 與 SP 平台持續推動全球手術量成長,da Vinci 5 使用率高於前代產品
      • SP 單孔平台手術量年增 68%,美國、韓國與歐洲早期採用動能強勁
      • 數位與 AI 生態系投資深化,推動臨床數據、遠距協作、AI 輔助決策等創新應用
      • 國際市場滲透率提升,歐洲、印度、加拿大、台灣等地表現亮眼,歐洲 NHS 年底預算帶動系統銷售
    • 風險:
      • 中國市場持續面臨招標量低、國產競爭與政策壓力,短期不易改善
      • 日本市場資本支出受限,儘管有新手術項目獲得報銷,短期成長仍保守
      • 肥胖症藥物(GLP-1)影響美國減重手術量,對部分手術需求造成壓力
      • 原物料(油價、記憶體)與運輸成本上升,全年毛利率仍受壓抑
  3. 核心 KPI / 事業群
    • 總手術量:年增 17%,da Vinci 手術量年增 16% 至 847,000,Ion 手術量年增 39% 至 43,000
    • 美國 da Vinci 手術量年增 14%,SP 平台手術量年增 68%,SP 系統美國使用率年增 22%
    • 國際(OUS)da Vinci 手術量年增 19%,SP 平台歐洲、日本、台灣早期成長強勁
    • Q1 新增 da Vinci 系統 431 台(年增 17%),其中 da Vinci 5 系統 232 台,SP 系統 34 台,Ion 系統 52 台
    • Recurring revenue(經常性收入)年增 23% 至 24 億美元,占總營收 86%
    • Non-GAAP 毛利率 67.8%(去年同期 66.4%)
    • 服務收入年增 19% 至 4.34 億美元,da Vinci 服務收入每台年增 6%
  4. 財務預測
    • 2026 年 da Vinci 手術量成長預估上修至 13.5%-15.5%
    • 2026 年 Non-GAAP 毛利率預估上調至 67.5%-68.5%(關稅影響 100bps)
    • Q1 資本支出 1.03 億美元,全年 CapEx 未提供明確預估
  5. 法人 Q&A
    • Q: 請談談 Intuitive 的數位與 AI 路線圖、資料基礎建設,以及 ROSE 併購進度。
      A: AI 將以臨床價值為核心,從高品質手術數據出發,逐步推動臨床洞察、手術輔助(如 AI 解剖辨識、鏡頭自動控制等),並強調規模化與安全性。ROSE 與相關技術預計短期內不會落地,但將為肺癌診斷帶來差異化價值。
    • Q: 毛利率展望與原物料(油價、記憶體)成本影響?
      A: Q1 毛利率受惠於營收成長與產品成本下降,油價與記憶體等成本上升對全年毛利率有影響,但目前影響相對小,已納入全年指引。
    • Q: 美國闌尾切除術(appendectomy)與日本新報銷手術的增量機會?
      A: 美國闌尾切除術市場尚未明確量化,現階段仍在早期推廣與臨床驗證。日本新增七項手術報銷,最大為雙側腹股溝疝氣修補術,每例約 1,500 美元,但整體增量機會仍需時間發酵,短期影響有限。
    • Q: 創新帶動的營收成長(innovation-led revenue growth)與手術量成長的關係?
      A: 創新產品(如 da Vinci 5、SP、AI 應用)帶來差異化價值,能提升單價與營收增速,部分市場則以成本優化回饋客戶。營收成長高於手術量成長的現象可望持續,但不提供明確展望。
    • Q: SP 單孔平台的成長潛力與 TAM 擴張?
      A: SP 平台手術量維持高成長,受益於新適應症與地區擴張,未來 1-2 年仍聚焦現有市場滲透。長期來看,SP 有機會開拓新適應症與擴大總可服務市場(TAM),但目前仍在早期階段。

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good day, and thank you for standing by. Welcome to the Intuitive First Quarter 2026 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

    大家好,感謝您稍候。歡迎參加 Intuitive 2026 年第一季財報電話會議。(接線員指示) 請注意,今天的會議將被錄音。

  • I would now like to hand the conference over to your speaker today, Dan Connally, Vice President, Investor Relations. Sir, please go ahead.

    現在我想將會議交給今天的講者——投資人關係副總裁 Dan Connally。先生,請開始。

  • Dan Connally - Vice President and Head of Investor Relations

    Dan Connally - Vice President and Head of Investor Relations

  • Good afternoon, and welcome to Intuitive's First Quarter Earnings Conference Call. Joining me today are Dave Rosa, our CEO; and Jamie Samath, our CFO. Before we begin, I would like to remind you that comments made on today's call may contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in our Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 3, 2026. Our SEC filings can be found through our website at intuitive.com or at the SEC's website. Investors are cautioned not to place undue reliance on such forward-looking statements.

    各位下午好,歡迎參加 Intuitive 第一季財報電話會議。今天與我一同出席的有我們的執行長 Dave Rosa,以及財務長 Jamie Samath。在開始之前,我想提醒各位,今天電話會議中的評論可能包含前瞻性陳述。由於某些風險與不確定性,實際結果可能與明示或暗示的內容有重大差異。這些風險與不確定性已在我們向美國證券交易委員會(SEC)提交的文件中說明,包括我們於 2026 年 2 月 3 日提交的最新 Form 10-K。我們的 SEC 申報文件可透過 intuitive.com 的網站或 SEC 網站查閱。提醒投資人不要過度依賴此類前瞻性陳述。

  • Please note that this conference call will be available for audio replay on our website in the Events section under our Investor Relations page. We are experiencing technical difficulties with distribution of today's press release. Note, you can find today's 8-K, including our press release, on our website or at the SEC's website. The Q1 2026 financial data tables have been posted to our website as well.

    請注意,本次電話會議的音訊重播將可在我們網站投資人關係頁面下的「活動(Events)」區取得。我們在發佈今日新聞稿的傳送上正遇到技術問題。請注意,您可在我們網站或 SEC 網站找到今日的 8-K(其中包含新聞稿)。2026 年第一季財務資料表也已張貼於我們網站。

  • Our format for this afternoon's earnings conference call is as follows: Dave will review business and operational highlights. Jamie will provide a review of our financial results and procedure highlights. I will review clinical highlights and discuss our updated financial outlook for 2026. And finally, we will host a question-and-answer session.

    今天下午財報電話會議的流程如下:Dave 將回顧業務與營運重點。Jamie 將回顧我們的財務結果與手術量重點。我將回顧臨床重點並討論我們更新後的 2026 年財務展望。最後,我們將進行問答環節。

  • With that, I will turn it over to Dave.

    接下來,我把時間交給 Dave。

  • David Rosa - Chief Executive Officer, Director

    David Rosa - Chief Executive Officer, Director

  • Good afternoon, and thank you for joining us. Q1 was a solid start to the year for Intuitive, driven by 17% total procedure growth and broad-based adoption across da Vinci and Ion as customers continue to advance minimally invasive care. In Q1, da Vinci procedures grew 16% to $847,000, and Ion procedures increased 39% to $43,000. Performance was strong in the US and Europe with mixed results in Asia.

    各位下午好,感謝各位加入我們。對 Intuitive 而言,第一季是穩健的開局,總手術量成長 17%,且隨著客戶持續推進微創照護,da Vinci 與 Ion 的採用呈現廣泛成長。第一季 da Vinci 手術量成長 16% 至 847,000 例,Ion 手術量增加 39% 至 43,000 例。美國與歐洲表現強勁,亞洲結果則較為分歧。

  • In the United States, da Vinci procedures grew 14% year-over-year, led by strength in general surgery. Growth was supported by a 31% increase in after-hours procedures and higher overall utilization. Da Vinci 5 utilization continues to exceed that of da Vinci Xi driving US utilization growth to 4%.

    在美國,da Vinci 手術量年增 14%,主要由一般外科的強勁表現帶動。成長受惠於下班後手術量增加 31% 以及整體使用率提升。da Vinci 5 的使用率持續高於 da Vinci Xi,帶動美國使用率成長至 4%。

  • Outside the US, da Vinci procedures grew 19%, led by continued strength in general surgery and gynecology as adoption expands beyond urology. The lower growth rate relative to prior quarters reflects ongoing challenges in China and Japan.

    在美國以外地區,da Vinci 手術量成長 19%,主要由一般外科與婦科持續強勁帶動,且隨著採用擴展至泌尿科以外領域。相較於前幾季較低的成長率,反映中國與日本仍面臨持續挑戰。

  • In China, the environment remains largely consistent with recent quarters reflecting relatively low tender activity across the category, domestic competition and policy-driven pricing pressure. Given our belief in the long-term opportunity, we continue to make investments to improve procedure growth, establish favorable patient charge codes and support other market access activities.

    在中國,整體環境與近幾季大致一致,反映該類別的招標活動相對偏低、國內競爭,以及政策驅動的價格壓力。基於我們對長期機會的信心,我們持續投入資源以提升手術量成長、建立有利的病患收費代碼,並支持其他市場准入相關活動。

  • In Japan, procedure growth improved sequentially, but remained below historical levels following fewer system placements in 2025. We are encouraged by recent policy developments, including incremental financial support for higher-volume robotic programs and new reimbursement for seven additional procedures. Both policies to be effective starting in June of 2026.

    在日本,手術量成長較前一季改善,但由於 2025 年系統裝機數較少,仍低於歷史水準。我們對近期政策進展感到鼓舞,包括對高量能機器人計畫提供額外財務支持,以及新增 7 項手術的給付。兩項政策預計自 2026 年 6 月起生效。

  • Jamie will describe these changes in more detail shortly. I have confidence in our ability to execute our international strategy. Investments in our organizational capabilities, clinical trials and research, and market access efforts are yielding supportive robotic surgery policies and reimbursements in many of the countries we serve. The arc of progress is evident with OUS procedures now representing 38% of total da Vinci volume, up from 25% a decade ago.

    Jamie 稍後將更詳細說明這些變化。我對我們執行國際策略的能力充滿信心。我們在組織能力、臨床試驗與研究,以及市場准入工作的投資,正促成我們所服務的許多國家出現支持機器人手術的政策與給付。進展軌跡清晰可見:目前美國以外(OUS)手術量已占 da Vinci 總量的 38%,高於十年前的 25%。

  • We are well positioned to expand access and drive deeper adoption in these countries with the addition of XiR to our system portfolio, and our overall ecosystem of technologies, training and services.

    隨著 XiR 納入我們的系統產品組合,以及我們整體的技術、訓練與服務生態系,我們已具備良好條件在這些國家擴大可及性並推動更深度的採用。

  • Turning to capital. We placed 431 da Vinci systems in Q1, including 232 da Vinci 5 systems, 34 SP systems and XiR systems. We also placed 52 Ion systems in the quarter. As da Vinci 5 moves into broader clinical use globally, customer adoption and feedback remain very encouraging.

    接著談資本設備。第一季我們共裝機 431 台 da Vinci 系統,其中包括 232 台 da Vinci 5 系統、34 台 SP 系統以及 XiR 系統。本季我們也裝機 52 台 Ion 系統。隨著 da Vinci 5 在全球進入更廣泛的臨床使用,客戶採用情況與回饋仍非常令人鼓舞。

  • Customers are building experience with the da Vinci 5 ecosystem, resulting in increased clinical throughput and expanded access to da Vinci surgery.

    客戶正在累積 da Vinci 5 生態系的使用經驗,進而提升臨床處置量並擴大 da Vinci 手術的可及性。

  • At the recent annual SAGES conference, several clinical abstracts demonstrated objectively lower tissue forces using da Vinci force feedback instrumentation across multiple procedure types. We continue to believe that objective knowledge of applied forces and surgery will lead to improved surgical outcomes and are investing to demonstrate this at scale.

    在近期年度 SAGES 會議上,多篇臨床摘要顯示,使用 da Vinci 力回饋器械在多種手術類型中可客觀地降低組織受力。我們持續相信,對施加力量與手術過程的客觀認知將帶來更佳的手術結果,並正投入資源以在更大規模上加以驗證。

  • In March, we received FDA 510(k) clearance for additional uses of our force feedback instruments. five of six instruments are now cleared for 15 uses, while our mega suture cut natal driver is clear for 10 uses. Combined with multiyear investments in supply chain and manufacturing, this clearance supports broader availability in Q2 that will increase over the rest of the year. We expect adoption of force feedback invitation to progress steadily through 2026 and beyond.

    3 月,我們取得 FDA 510(k) 核准,允許我們的力回饋器械用於更多適應用途。六款器械中的五款目前已核准 15 項用途,而我們的 mega suture cut natal driver 已核准 10 項用途。結合我們在供應鏈與製造方面的多年投資,此項核准將支持第二季更廣泛的供應,並在今年其餘時間持續提升。我們預期力回饋器械的採用將在 2026 年及之後穩步推進。

  • Turning to our digital ecosystem. We continue to invest in the data and digital infrastructure that underpins our longer-term innovation road map. Da Vinci 5 captures real-world surgical data at greater scale and fidelity, enabling deeper insight into how procedures are performed and practiced. That insight paired with clinical context from connected electronic medical records, provides better understanding of variation, workflow and outcomes and informs current in planned digital and AI-enabled capabilities.

    接著談我們的數位生態系。我們持續投資於支撐長期創新藍圖的資料與數位基礎設施。da Vinci 5 以更大的規模與更高的精確度擷取真實世界手術資料,使我們能更深入洞察手術如何被執行與實務操作。這些洞察若再結合來自連結式電子病歷的臨床情境,可更好地理解差異性、工作流程與結果,並為現有與規劃中的數位與 AI 賦能能力提供資訊。

  • My Intuitive Plus continues to play an expanding role in training and program support with growing adoption of Intuitive telepresence capabilities that enable proctoring, mentoring and collaboration across surgeons insights. Collectively, these efforts are foundational to our long term digital and AI road map where we expect to add telesurgery, deeper decision support and augmented dexterity, including aspects of future automation, all in pursuit of advancing the Quintuple Aim.

    My Intuitive Plus 在訓練與計畫支持方面持續扮演日益擴大的角色;同時,Intuitive 遠距臨場(telepresence)能力的採用也在增加,可支援督導(proctoring)、指導(mentoring)以及跨外科醫師的協作與洞見分享。整體而言,這些努力是我們長期數位與 AI 藍圖的基礎;我們預期將加入遠距手術(telesurgery)、更深入的決策支持與增強靈巧度(augmented dexterity),包括未來自動化的部分面向,皆以推進「五重目標(Quintuple Aim)」為宗旨。

  • I'm excited by the progress our development teams are making.

    我對我們研發團隊所取得的進展感到振奮。

  • Turning to our single port platform. SP momentum continued in the quarter with procedures growing 68% year-over-year. Growth was driven by expansion in Korea and the US and ongoing early adoption across select international markets. Recently, US surgeons performed the first non-IDE nipple-sparing mastectomy cases as we advance our measured rollout focused on training and support of our customers.

    接著談我們的單孔平台。本季 SP 動能延續,手術量年增 68%。成長來自韓國與美國的擴張,以及在部分國際市場持續的早期採用。近期,隨著我們推進以客戶訓練與支持為重點的審慎推廣,美國外科醫師完成了首批非 IDE 的保留乳頭乳暈乳房切除術(nipple-sparing mastectomy)案例。

  • We also moved our single port stapler into broad launch, which will support deeper penetration in thoracic and colorectal procedures as customers expand their programs. Our teams are focused on new product and procedure launches, expanding our customer base and securing new geographic clearances. Over the midterm, SP will incorporate much of the da Vinci 5 ecosystem, including current and future digital and AI capabilities. We're excited about the potential of SP to drive meaningful improvement in the Quintuple Aim.

    我們也已將我們的單孔吻合器推進至全面上市,這將在客戶擴大其計畫時,支持在胸腔與大腸直腸手術中的更深度滲透。我們的團隊專注於新產品與新術式的上市,擴大客戶基礎並取得新的地理區域核准。在中期,SP 將納入 da Vinci 5 生態系統的大部分內容,包括現有與未來的數位與 AI 能力。我們對 SP 有潛力推動「五重目標」的實質改善感到振奮。

  • Moving to Ion. We're pleased with the results and progress this quarter. Ion's North Star is to help physicians improve lung cancer patient survival. Clinical publications continue to reinforce progress here, including a recent Mayo Clinic publication of approximately 2,000 patients, which demonstrated that use of Ion supports earlier identification of malignancy with the potential to improve patient survival. Dan will walk through the study in more detail later in the call.

    接著談 Ion。我們對本季的成果與進展感到滿意。Ion 的北極星目標是協助醫師提升肺癌患者的存活率。臨床發表持續強化我們在此的進展,包括梅約診所近期發表、約 2,000 名患者的研究,顯示使用 Ion 有助於更早辨識惡性病灶,並具備改善患者存活率的潛力。Dan 稍後會在電話會議中更詳細說明該研究。

  • Our teams are making progress on our rapid on-site tissue evaluation technology or ROSE and endobronchial ultrasound integration as we look to further streamline the time from detection to diagnosis.

    我們的團隊在快速現場組織評估技術(ROSE)以及支氣管內超音波整合方面持續取得進展,以期進一步精簡從偵測到診斷的時間。

  • Looking ahead, our company priorities for 2026 are unchanged. First, the global expansion of our platforms, digital feature releases and ecosystem enhancements. Second, increased adoption for focused procedures by country through training, commercial activities and market access efforts.

    展望未來,我們公司 2026 年的優先事項維持不變。第一,推動我們平台的全球擴張、數位功能釋出與生態系增強。第二,透過訓練、商業活動與市場准入工作,按國家提升重點術式的採用。

  • Third, building industrial scale, enhancing product quality and achieving manufacturing optimization. And finally, advancing innovation to reach more patients in current and new disease states.

    第三,建立工業化規模、提升產品品質並達成製造最佳化。最後,推進創新,以在現有與新的疾病領域觸及更多患者。

  • Before I turn the call over to Jamie, I want to recognize an important leadership transition at Intuitive. Dr. Myriam Curet is retiring this quarter after more than 20 years as Intuitive's Chief Medical Officer. I'd like to thank Myriam for all her efforts in advancing our mission as a physician, a patient advocate and a business leader. I'm also pleased to announce Dr. Jamie Wong's promotion to Chief Medical Officer and member of our executive leadership team.

    在我把電話交給 Jamie 之前,我想提及 Intuitive 一項重要的領導層交接。Dr. Myriam Curet 在擔任 Intuitive 首席醫療長超過 20 年後,將於本季退休。我想感謝 Myriam 以醫師、病患倡議者與企業領導者的身分,為推進我們使命所付出的所有努力。我也很高興宣布 Dr. Jamie Wong 晉升為首席醫療長,並成為我們執行領導團隊的一員。

  • Jamie provides -- combines a deep clinical background as a practicing da Vinci urologist with his experience of more than a decade at Intuitive, leading a variety of functions. As CMO, he will lead our global medical office, overseeing customer training, clinical evidence generation and research and reimbursement and market access efforts.

    Jamie 兼具深厚的臨床背景(作為執業中的 da Vinci 泌尿科醫師)以及在 Intuitive 超過十年的經驗,曾領導多項不同職能。作為首席醫療長,他將領導我們的全球醫務部門,監督客戶訓練、臨床證據產出與研究,以及給付與市場准入相關工作。

  • And with that, I'll turn the time over to Jamie to take you through our finances in greater detail.

    接下來,我把時間交給 Jamie,請他更詳細帶大家了解我們的財務狀況。

  • Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

    Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

  • Good afternoon. I will describe our performance on a non-GAAP basis, and I'll summarize our GAAP results later in my remarks. A reconciliation between our non-GAAP and GAAP results is available on our website. All references to total procedures and their related growth rates include both da Vinci and Ion procedures.

    各位下午好。我將以非 GAAP 基礎說明我們的表現,並在稍後的發言中摘要我們的 GAAP 結果。非 GAAP 與 GAAP 結果之間的調節表可在我們的網站上取得。所有對總手術量及其相關成長率的引用,均包含 da Vinci 與 Ion 手術。

  • Before detailing our quarterly results, I would like to briefly address the cyber incident that occurred during the first quarter, which resulted in unauthorized access to some customer business and contact information as well as certain Intuitive employee and corporate data contained in certain of our IT business applications. The incident did not disrupt our business or manufacturing operations and did not affect our products.

    在說明本季業績之前,我想先簡要說明第一季發生的資安事件。該事件導致未經授權存取部分客戶的業務與聯絡資訊,以及我們部分 IT 業務應用程式中所包含的某些 Intuitive 員工與公司資料。該事件未干擾我們的業務或製造營運,也未影響我們的產品。

  • It also did not have a significant impact on our first quarter financial results. We have contained the incident, notified customers and informed appropriate data privacy regulators. We are also taking additional steps to further strengthen our cybersecurity protocols.

    此外,該事件對我們第一季財務結果並無重大影響。我們已控制住該事件,通知客戶並告知適當的資料隱私監管機關。我們也正採取額外措施,以進一步強化我們的資安防護規範。

  • In Q1, total procedures grew 17%, reflecting 16% growth in da Vinci procedures and 39% growth in Ion procedures. Quarter one revenue increased 23% to $2.77 billion, with recurring revenue also higher by 23% to $2.4 billion, accounting for 86% of total revenue. On a constant currency basis, revenue growth was 22%. Non-GAAP operating margin was strong at 39% and primarily reflecting leverage of fixed costs. The strength of our financial results reflected continuing global expansion and procedure adoption of our da Vinci 5, Ion and SP platforms.

    第一季總手術量成長 17%,其中 da Vinci 手術成長 16%,Ion 手術成長 39%。第一季營收成長 23% 至 27.7 億美元;經常性營收亦成長 23% 至 24 億美元,占總營收的 86%。以固定匯率計,營收成長為 22%。非 GAAP 營業利益率維持強勁,達 39%,主要反映固定成本的槓桿效益。我們強勁的財務表現反映 da Vinci 5、Ion 與 SP 平台在全球持續擴張與手術採用率提升。

  • Turning to the clinical side of our business. In the US, total procedures increased 15%, reflecting 14% growth in da Vinci procedures and 37% growth in Ion procedures. For our da Vinci platforms, we continue to see strong growth in cholecystectomy and appendectomy procedures, which combined grew by 31% and driven in part by continued expansion of use da Vinci during after hours and on weekends.

    接著談我們業務的臨床面。在美國,總手術量成長 15%,其中 da Vinci 手術成長 14%,Ion 手術成長 37%。就 da Vinci 平台而言,我們持續看到膽囊切除與闌尾切除手術的強勁成長,兩者合計成長 31%,部分原因是 da Vinci 在非上班時間與週末的使用持續擴大。

  • We are starting to see emerging evidence that a broad set of clinical outcomes for appendectomy are improved with da Vinci surgery as compared to laparoscopy.

    我們開始看到新興證據顯示,與腹腔鏡手術相比,使用 da Vinci 進行闌尾切除在多項臨床結果上有所改善。

  • Over the last year, in the US we've invested in incremental clinical support for surgeons performing benign gynecology procedures given the opportunity to improve patient outcomes.

    過去一年在美國,鑑於改善患者預後的機會,我們對執行良性婦科手術的外科醫師投入了額外的臨床支援。

  • While total US gynecology procedures grew 10% in Q1, investments in this area drove a 19% increase in nonhysterectomy benign procedures, including sacrocolpopexy, endometriosis, oophorectomy and myomectomy during the quarter. Da Vinci bariatrics procedures in the US continue to be impacted by the growth in use of GLP-1s and declined approximately 10%.

    雖然第一季美國婦科手術總量成長 10%,但在此領域的投資帶動本季非子宮切除的良性手術成長 19%,包括薦骨陰道固定術、子宮內膜異位症手術、卵巢切除術與子宮肌瘤切除術。美國的 da Vinci 減重手術仍受 GLP-1 類藥物使用增加影響,約下滑 10%。

  • Da Vinci utilization in the US increased 4% in Q1 and higher than recent quarters, driven by a growing installed base of da Vinci 5 systems, where utilization is approximately 11% higher than Xi.

    第一季美國 da Vinci 使用率提升 4%,高於近幾季,主要由 da Vinci 5 系統裝機量增加所帶動;其使用率約比 Xi 高 11%。

  • With respect to the expiration of subsidies for enhanced premiums under ACA, while we did not see any significant impact on procedure volumes in Q1, at this time, we remain cautious as to what the potential impact, if any, might be.

    關於《平價醫療法案》(ACA)下強化保費補貼到期一事,雖然我們在第一季未看到手術量有任何顯著影響,但目前我們仍對其可能造成的影響(若有)保持審慎。

  • Outside the US, total procedures grew 20% with da Vinci procedure growth of 19%, reflecting strong results in India, Canada, the UK, Korea and Taiwan and solid growth in distributor markets, Italy and Germany. The market in China continues to be challenging.

    在美國以外地區,總手術量成長 20%,其中 da Vinci 手術成長 19%,反映印度、加拿大、英國、韓國與台灣表現強勁,經銷市場、義大利與德國亦有穩健成長。中國市場仍持續具挑戰性。

  • In Q1, procedure growth was below the corporate average, reflecting lower tenders and competitive and pricing pressures. There are ongoing discussions with provinces regarding potential new charge code and reimbursement policies in China for robotic procedures. We are actively engaged with policymakers but do not expect clarity on the outcome of these matters until 2027.

    第一季手術量成長低於公司平均,反映招標量較少,以及競爭與價格壓力。目前正與各省就中國機器人手術可能新增的收費代碼與給付政策進行持續討論。我們正積極與政策制定者互動,但預期要到 2027 年才會對這些事項的結果有明確結論。

  • Procedure growth in Japan was also below the corporate average, reflecting lower capital placements over the last several quarters. In Q1, the Japanese Ministry of Health, Labor and Welfare, or MHLW, recently introduced incremental reimbursement for hospitals that exceed robotic procedure volumes of 200 qualifying cases per year. In addition, seven new procedures have been granted robotic reimbursement starting in June of 2026.

    日本的手術量成長也低於公司平均,反映過去幾季資本設備投放較少。第一季,日本厚生勞動省(MHLW)近期針對每年超過 200 例符合資格的機器人手術量之醫院,新增了額外的給付。此外,自 2026 年 6 月起,另有 7 項新術式獲得機器人手術給付。

  • Furthermore, rectal resection has been granted premium reimbursement when performed robotically. While we are encouraged by these steps, we remain cautious in our outlook for the Japanese market in the short term given the financial position of public hospitals in recent periods.

    此外,直腸切除術在以機器人方式執行時,已獲核准可取得加成給付。雖然我們對這些措施感到鼓舞,但鑑於近期香港公立醫院的財務狀況,我們對日本市場短期展望仍保持審慎。

  • Globally, we continue to see healthy procedure growth for our SP platform at 68% for Q1 with strength in Korea and continuing robust early-stage growth in Europe, Japan and Taiwan. In the US, SP average system utilization continued to accelerate following recent additional clearances growing 22% as compared to quarter one of last year.

    在全球範圍內,我們持續看到 SP 平台在第一季的手術量成長保持強勁,成長率達 68%,其中韓國表現突出,歐洲、日本與台灣也延續強健的早期成長動能。在美國,隨著近期取得額外許可,SP 的平均系統使用率持續加速提升,較去年第一季成長 22%。

  • During the quarter, we moved our new SP stapler into broad launch in the US, where it was used in almost 40% of cases where we would expect a staple to be used. We are planning to move the SP stapler into measured launch in Korea and Europe in Q2 as we expand manufacturing capacity.

    本季期間,我們在美國將新款 SP 釘合器(stapler)推進至全面上市,在預期會使用釘合器的手術案例中,幾乎有 40% 使用了該產品。隨著我們擴充製造產能,我們計畫於第二季在韓國與歐洲以「有節奏的上市」(measured launch)方式導入 SP 釘合器。

  • As a result of our clinical performance, total I&A revenue in quarter one grew 23% to $1.7 billion. Da Vinci I&A revenue per procedure was approximately $1,880 compared to $1,780 last year, driven by customer ordering patterns, a higher mix of SP and da Vinci 5 procedures and FX, partially offset by lower bariatric and high cholecystectomy procedures.

    受惠於我們的臨床表現,第一季 I&A(器械與配件)總營收成長 23%,達 17 億美元。da Vinci 每例手術的 I&A 營收約為 1,880 美元,去年為 1,780 美元;主要受客戶訂購型態、SP 與 da Vinci 5 手術占比提高以及匯率(FX)帶動,但部分被減少的減重手術(bariatric)與高膽囊切除術(cholecystectomy)手術量所抵銷。

  • Turning to capital performance and starting with our da Vinci business. We placed 431 da Vinci systems in quarter one, a 17% increase from the 367 systems placed in the same quarter last year. 232 of the 431 placements were da Vinci 5, including 40 in OUS markets. The installed base of da Vinci 5 is now almost 1,500 systems used by almost 13,000 surgeons since launch.

    接著談資本表現,先從我們的 da Vinci 業務開始。第一季我們安裝(placed)了 431 套 da Vinci 系統,較去年同期安裝的 367 套成長 17%。在 431 套安裝中,有 232 套為 da Vinci 5,其中包含 40 套在美國以外(OUS)市場。自上市以來,da Vinci 5 的裝機基數目前已接近 1,500 套,並已由近 13,000 名外科醫師使用。

  • Customers acquired 34 refurbished excise systems in Q1 compared to two in the year ago period, 26 of the 34 placements were in OUS markets in segments where we see greater cost sensitivity.

    第一季客戶購置了 34 套翻新(refurbished)的 excise 系統,去年同期為 2 套;其中 34 套中的 26 套安裝於 OUS 市場,主要位於我們觀察到成本敏感度較高的細分市場。

  • There were 119 trading transactions in quarter one, up from 67 a year ago, primarily driven by US customers upgrading to da Vinci 5. In the US, we placed 226 systems, up from 204 last year, driven by adoption of da Vinci 5. Outside the US, we placed 205 systems, an increase of 26% compared to the 163 systems placed last year. OUS placements included 117 systems in Europe, 62 in Asia and 26 in the rest of the world compared to 88, 52 and 23, respectively, last year.

    第一季共有 119 筆以舊換新(trade-in)交易,高於去年同期的 67 筆,主要由美國客戶升級至 da Vinci 5 所帶動。在美國,我們安裝了 226 套系統,高於去年的 204 套,主要受 da Vinci 5 採用推動。在美國以外,我們安裝了 205 套系統,較去年安裝的 163 套成長 26%。OUS 安裝包含歐洲 117 套、亞洲 62 套以及世界其他地區 26 套;去年分別為 88、52 與 23 套。

  • Relative strength in Europe was driven primarily by the UK, where we placed 34 systems as the NHS closed out its budgetary year. We placed 13 systems in Japan and four systems in China, reflecting lower overall tender volumes.

    歐洲的相對強勁主要由英國帶動;在 NHS 結束其預算年度之際,我們在英國安裝了 34 套系統。我們在日本安裝了 13 套系統、在中國安裝了 4 套系統,反映整體招標量較低。

  • Within the 431 da Vinci placements, we placed 34 SP systems in Q1 and higher than the 19 systems last year, driven primarily by increased placements in the US and Taiwan. For our Ion platform, we placed 52 systems in Q1 compared to 49 systems last year. Q1 Ion placements included 13 systems in OUS markets. Given our capital performance, quarter one systems revenue grew 24% to $651 million.

    在 431 套 da Vinci 安裝中,我們第一季安裝了 34 套 SP 系統,高於去年的 19 套,主要由美國與台灣安裝量增加所帶動。在 Ion 平台方面,我們第一季安裝了 52 套系統,去年為 49 套。第一季 Ion 的安裝包含 OUS 市場的 13 套系統。受惠於我們的資本表現,第一季系統營收成長 24%,達 6.51 億美元。

  • For our da Vinci business, leasing represented 56% of da Vinci placements as compared to 47% last quarter and 54% last year, driven primarily by customer preference. Da Vinci leasing revenue increased 28%, reflecting a 14% expansion of the installed base under operating lease arrangements and a 12% increase in lease revenue per system, driven by a higher mix of da Vinci 5 systems and higher utilization for usage-based arrangements.

    就 da Vinci 業務而言,租賃占 da Vinci 安裝量的 56%,相較上季為 47%、去年為 54%,主要由客戶偏好所驅動。da Vinci 租賃營收成長 28%,反映採用營運租賃安排的裝機基數擴大 14%,以及每套系統租賃營收增加 12%;後者主要由 da Vinci 5 占比提高,以及按使用量計費(usage-based)安排下更高的使用率所帶動。

  • The average selling price for purchased da Vinci 5 systems was $1.7 million in Q1 as compared to $1.6 million last year driven both by a higher mix of da Vinci 5 systems and dual-console systems, partially offset by higher trade-ins. Lease buyout revenue was $51 million as compared to $39 million last quarter and last year.

    第一季購買型 da Vinci 5 系統的平均售價為 170 萬美元,去年為 160 萬美元;上升原因同時包括 da Vinci 5 與雙主控台(dual-console)系統占比提高,但部分被較高的以舊換新所抵銷。租賃買斷(lease buyout)營收為 5,100 萬美元,相較上季與去年同期均為 3,900 萬美元。

  • Quarter one service revenue increased 19% to $434 million, reflecting an increase of the da Vinci installed base of 12% and the Ion installed base of 22%. Service revenue per system for our da Vinci installed base increased 6% year-over-year, primarily reflecting a higher mix of da Vinci 5 systems.

    第一季服務營收成長 19%,達 4.34 億美元,反映 da Vinci 裝機基數增加 12% 以及 Ion 裝機基數增加 22%。我們 da Vinci 裝機基數的每套系統服務營收年增 6%,主要反映 da Vinci 5 系統占比提高。

  • Turning now to the rest of the P&L. Non-GAAP gross margin for the quarter was 67.8% and an increase from 66.4% in Q1 of last year. The year-over-year increase reflects product cost reductions and fixed overhead leverage, partly offset by the impact of tariffs. While Q1 results were not significantly impacted by higher oil and memory prices, we do expect those to have a greater unfavorable impact in the remainder of the year.

    接著看損益表(P&L)的其餘部分。本季非 GAAP 毛利率為 67.8%,高於去年第一季的 66.4%。年增主要反映產品成本下降與固定間接費用槓桿效益,但部分被關稅影響所抵銷。雖然第一季結果未受到油價與記憶體價格上升的顯著影響,但我們預期這些因素在今年剩餘期間將帶來更大的不利影響。

  • During the quarter, our da Vinci 5 system achieved contribution margins comparable with our Xi System, and our Ion platform achieve contribution margins that are close to the corporate average, reflecting significant efforts by our engineering and operations teams.

    本季期間,我們的 da Vinci 5 系統達成與 Xi 系統相當的貢獻毛利率(contribution margin),而 Ion 平台的貢獻毛利率也接近公司平均水準,反映我們工程與營運團隊所做出的重大努力。

  • Continuing initiatives to further improve gross margins, excluding the impact of tariffs are focused on leverage of fixed overhead, improving product and service margins for da Vinci 5 and additional reductions to product costs for our SP and Ion platforms. Future gross margins will reflect our execution on these initiatives competitive pricing dynamics, global tariff rates and product, regional and trade-in mix.

    為進一步提升毛利率、且不含關稅影響的持續性措施,重點包括:強化固定間接費用的槓桿效益、提升 da Vinci 5 的產品與服務毛利率,以及進一步降低 SP 與 Ion 平台的產品成本。未來毛利率將反映我們對上述措施的執行成果、競爭性定價動態、全球關稅稅率,以及產品、地區與以舊換新組合。

  • Quarter one non-GAAP operating expenses increased 10% year-over-year, a little lower than our expectations due to the timing of certain expenses. The year-over-year increase was driven by higher headcount, increased variable compensation and higher facility costs, partially offset by lower legal expenses.

    第一季非 GAAP 營業費用年增 10%,由於部分費用認列時點的影響,略低於我們的預期。年增主要由人力增加、變動薪酬提高與設施成本上升所驅動,但部分被法律費用下降所抵銷。

  • We added 425 employees during the quarter, of which 230 were related to the acquisition of our distribution business in Italy, Spain and Portugal. Non-GAAP other income was $85 million for the quarter as compared to $86 million last quarter, reflecting lower interest income. Our non-GAAP effective tax rate for quarter one was 22%, consistent with our expectations. Non-GAAP net income for the first quarter was $901 million compared with $662 million last year. Non-GAAP earnings per share was $2.50 per share compared to $1.81 per share in quarter one of last year.

    本季我們新增 425 名員工,其中 230 名與我們在義大利、西班牙與葡萄牙收購經銷業務相關。本季非 GAAP 其他收益為 8,500 萬美元,較上季的 8,600 萬美元略降,反映利息收入較低。第一季非 GAAP 有效稅率為 22%,符合我們的預期。第一季非 GAAP 淨利為 9.01 億美元,去年為 6.62 億美元。第一季非 GAAP 每股盈餘為 2.50 美元,去年第一季為 1.81 美元。

  • Now turning to our GAAP results. GAAP net income for the quarter was $822 million or $2.28 per share compared to $698 million or $1.92 per share in Q1 of last year. We ended the quarter with $8 billion in cash and investments, down from $9 billion last quarter, driven by stock repurchases of $1.1 billion, the acquisition of our distributor business in Italy, Spain and Portugal, and capital expenditures of $103 million, partially offset by cash generated from operating activities and proceeds from employee equity activity.

    接著看我們的 GAAP 結果。本季 GAAP 淨利為 8.22 億美元,或每股 2.28 美元;去年第一季為 6.98 億美元,或每股 1.92 美元。本季期末我們持有 80 億美元的現金與投資,較上季的 90 億美元下降;主要因股票回購 11 億美元、收購義大利、西班牙與葡萄牙的經銷業務,以及 1.03 億美元的資本支出所致,但部分被營運活動產生的現金與員工股權活動所得款項所抵銷。

  • Taking a moment to recap our recent financial performance. A core element of our strategy focuses on excellence in product innovation to launch highly differentiated products that drive the Quintuple Aim for the benefit of customers and patients.

    稍作回顧我們近期的財務表現。我們策略的核心要素之一,是專注於卓越的產品創新,推出高度差異化的產品,以推動「五重目標」(Quintuple Aim),為客戶與病患帶來效益。

  • Revenue growth ahead of total procedure growth reflects, in large part, the differentiated value of da Vinci 5 as that new platform becomes a greater proportion of our business, revenue growth benefits from accretive pricing, higher levels of integration and incremental trading volumes. We see opportunities to continue to drive innovation-led revenue performance with our SP stapler planned SP vessel sealer and growth in use of existing and planned AI and digital capabilities.

    營收成長領先於整體手術量成長,主要反映出隨著 da Vinci 5 這一新平台在我們業務中的占比提高,其差異化價值所帶來的影響;營收成長亦受惠於具增益性的定價、更高程度的整合,以及新增的以舊換新交易量。我們看到機會可持續透過創新驅動的方式推升營收表現,包括我們規劃中的 SP 釘合器、SP 血管封合器,以及既有與規劃中的 AI 與數位能力使用量的成長。

  • We also have plans to increase the value of our Ion platform in the lung through our pursuit of a staging indication and the integration of AI-based ROSE technology.

    我們也計畫透過追求分期(staging)適應症,以及整合以 AI 為基礎的 ROSE 技術,來提升 Ion 平台在肺部應用的價值。

  • With that, I'll turn it over to Dan to discuss recent clinical publications and our update outlook for 2026.

    接下來,我把時間交給 Dan,請他說明近期的臨床發表,以及我們對 2026 年的最新展望。

  • Dan Connally - Vice President and Head of Investor Relations

    Dan Connally - Vice President and Head of Investor Relations

  • Thank you, Jamie. Earlier this month, [ Dr. Sebastian Fernandez Bosie] from Mayo Clinic in Jacksonville, along with co-authors across Mayo clinic sites in Jacksonville, Phoenix and Rochester, published a study in Mayo Clinic proceedings titled 2,000 peripheral pulmonary lesions sampled by shape sensing robotic-assisted bronchoscopy and mobile cone beam computed tomography, the Mayo Clinic experience.

    謝謝你,Jamie。本月稍早,來自梅奧診所(Mayo Clinic)傑克森維爾院區的 [Sebastian Fernandez Bosie 醫師],與來自梅奧診所在傑克森維爾、鳳凰城與羅徹斯特等院區的共同作者,於《Mayo Clinic Proceedings》發表一項研究,題為「以形狀感測機器人輔助支氣管鏡與移動式錐形束電腦斷層(mobile cone beam CT)取樣 2,000 例周邊肺部病灶:梅奧診所經驗」。

  • In the study, which ran from July 2019 through August 2024, 12 proceduralists used Ion to biopsy 2,115 peripheral pulmonary lesions from 1,904 patients. Lesions biopsies were an average size of just under 18 millimeters with more than half located in the upper lobes at a median distance of 17 millimeters from the chest wall.

    該研究期間自 2019 年 7 月至 2024 年 8 月,共有 12 位操作者使用 Ion,對 1,904 名患者的 2,115 個周邊肺部病灶進行活檢。受檢病灶的平均大小略低於 18 毫米,且超過一半位於上葉,距離胸壁的中位數為 17 毫米。

  • Diagnostic yield according to the recently published strict ATS ACCP consensus statement definition was 79% with sensitivity of malignancy reported at 85%. Further, 74% of patients had concurrent endobronchial ultrasound lymph node staging with the authors noting, the ability to perform diagnosis and staging within the same anesthetic event reduces the risk of repeated interventions, facilitating lung cancer diagnosis and advanced disease management.

    依據近期發布之嚴格 ATS/ACCP 共識聲明對診斷率(diagnostic yield)的定義,診斷率為 79%,惡性腫瘤的敏感度(sensitivity)為 85%。此外,74% 的患者同時接受支氣管內超音波(EBUS)淋巴結分期;作者指出,在同一次麻醉事件中完成診斷與分期,可降低重複介入的風險,並有助於肺癌診斷與晚期疾病管理。

  • Additionally, results demonstrated a strong safety profile with a pneumothorax requiring intervention rate of 1.4% and severe bleeding defined as Nashville Grade 3 or higher of 0.3%. Notably, the rate of early stage primary lung cancer diagnosis in the study increased by 23 percentage points from 46% in 2019 to 69% in 2024. The authors concluded, in this high volume multicenter five-year study, shape sensing robotic-assisted bronchoscopy has shown a consistently optimal diagnostic yield with low complication rates.

    另外,結果顯示安全性表現強勁:需要介入處置的氣胸(pneumothorax)發生率為 1.4%,而嚴重出血(定義為 Nashville 分級 3 級或以上)為 0.3%。值得注意的是,研究中早期原發性肺癌的診斷率由 2019 年的 46% 提升至 2024 年的 69%,增加了 23 個百分點。作者總結指出,在這項高量能、多中心、為期五年的研究中,形狀感測機器人輔助支氣管鏡展現出一貫且最佳化的診斷率,且併發症發生率低。

  • To our knowledge, this is the largest cohort assessing shape-sensing robotic-assisted bronchoscopy following the recent strict consensus on diagnostic yield. The ability to sample multiple peripheral pulmonary lesions and include hilar and mediastinal staging within the same anesthetic event, physicians shape sensing robotic-assisted bronchoscopy as the preferred method of choice over CT-guided thoracic biopsy for assessing suspicious peripheral pulmonary lesions.

    據我們所知,這是依循近期對診斷率所制定之嚴格共識後,評估形狀感測機器人輔助支氣管鏡的最大規模隊列研究。能在同一次麻醉事件中取樣多個周邊肺部病灶,並同時納入肺門與縱膈分期,使醫師將形狀感測機器人輔助支氣管鏡視為評估可疑周邊肺部病灶時,相較於 CT 導引胸腔活檢更偏好的首選方法。

  • I will now turn to our updated financial outlook for 2026, starting with da Vinci procedures. In January, we forecast full year 2026 da Vinci procedure growth to be within a range of 13% to 15%. We are increasing our forecast and now expect full year da Vinci procedure growth within a range of 13.5% to 15.5%. We continue to expect primary growth drivers in 2026 to be generally consistent with those in 2025, including general surgery in the US and procedures outside of urology internationally.

    接下來我將說明我們更新後的 2026 年財務展望,先從 da Vinci 手術量開始。在 1 月時,我們預估 2026 全年 da Vinci 手術量成長將落在 13% 至 15% 的區間。我們上調預估,現在預期 2026 全年 da Vinci 手術量成長將落在 13.5% 至 15.5% 的區間。我們仍預期 2026 年的主要成長動能大致與 2025 年一致,包括美國的一般外科,以及國際市場中泌尿科以外的手術。

  • Our updated range continues to consider the potential impact of changes to ACA premium subsidies and patient behavior in the US, capital pressure in parts of Europe related to macroeconomic impact and shifting governmental priorities, China tender volumes and competitive intensity in that market, recent capital challenges in Japan and how long those persist in 2026, and pharmaceutical products for obesity management.

    我們更新後的區間仍納入多項潛在影響因素:美國 ACA 保費補貼變動及患者行為的可能影響、歐洲部分地區因總體經濟影響與政府優先事項轉移而產生的資本壓力、中國招標量與該市場的競爭強度、日本近期資本面挑戰及其在 2026 年可能持續的時間,以及用於肥胖管理的藥品。

  • Turning to gross profit. On our last call, we forecast non-GAAP gross profit margin to be within a range of 67% and 68% of revenue, which reflected 120 basis points of impact from tariffs. We are updating our estimate for non-GAAP gross profit margin to be within a range of 67.5% and 68.5% of revenue, which now reflects 100 basis points of impact from tariffs as well as higher input costs in other areas, including freight and semiconductor memory.

    接著談毛利。在上次電話會議中,我們預估非 GAAP 毛利率將落在營收的 67% 至 68% 區間,其中包含關稅帶來的 120 個基點影響。我們更新非 GAAP 毛利率預估至營收的 67.5% 至 68.5% 區間;此預估目前反映關稅影響為 100 個基點,同時也反映其他領域較高的投入成本,包括運輸與半導體記憶體。

  • Other factors for the year include faster growth of newer products daVinci 5 and Ion, modest incremental depreciation from recent facility expansion and the impact from higher da Vinci system upgrades, partially offset by cost reductions. Our actual non-GAAP gross profit margin will vary quarter-to-quarter depending largely on product, regional and trade-in mix and pricing.

    年度其他因素包括:較新產品 da Vinci 5 與 Ion 的更快成長、近期設施擴建帶來的溫和新增折舊,以及較高的 da Vinci 系統升級所造成的影響;上述部分將由成本降低所抵銷。我們實際的非 GAAP 毛利率將隨季度而波動,主要取決於產品組合、區域組合、以舊換新組合以及定價。

  • In regard to operating expenses, we now expect non-GAAP operating expense growth to be between 11% and 14%. We continue to estimate noncash stock compensation expense between $890 million and $920 million. We now forecast other income, which is comprised mostly of interest income to total between $315 million and $335 million due primarily to lower average cash balances following share repurchase activity in Q1.

    在營業費用方面,我們目前預期非 GAAP 營業費用成長介於 11% 至 14%。我們仍估計非現金的股票酬勞費用介於 8.90 億至 9.20 億美元。我們也將其他收入(主要為利息收入)預估為 3.15 億至 3.35 億美元,主要因第一季進行庫藏股回購活動後,平均現金餘額降低。

  • With regard to income tax, we continue to expect our non-GAAP income tax rate to be between 22% and 23% of pretax income.

    在所得稅方面,我們仍預期非 GAAP 所得稅率將為稅前所得的 22% 至 23%。

  • That concludes our prepared remarks. We will now open the call to your questions

    以上為我們事先準備的說明。接下來我們將開放提問。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Travis Steed, Bank of America.

    Travis Steed,美國銀行。

  • Travis Steed - Analyst

    Travis Steed - Analyst

  • Hey, congrats on good quarter. Maybe to start with kind of want to talk a little bit about some of the future. You talked a lot about data and digital infrastructure, augmented dexterity. Just kind of curious how you see the digital and data road map for Intuitive and -- but also some hints on biopsy and the ROSE acquisition. So love to kind of your big picture view of how that kind of plays out and anything you can say on timing?

    嗨,恭喜本季表現不錯。也許先從未來的一些面向談起。你們談了很多關於資料與數位基礎設施、增強靈巧度(augmented dexterity)。我想了解你們如何看待 Intuitive 的數位與資料路線圖——以及關於活檢與 ROSE 收購的一些線索。希望聽聽你們對整體大方向如何發展的看法,以及在時程上你們能分享的任何資訊?

  • David Rosa - Chief Executive Officer, Director

    David Rosa - Chief Executive Officer, Director

  • Yes. Happy to do it, Travis. Thank you for the question. So I'll start with AI. And I'm really -- and you asked the question, but I'm going to speak specifically about AI as it shows up in our products and with our customers and not so much AI on the corporate side.

    好的。很樂意回答,Travis。謝謝你的提問。我先從 AI 談起。你問到了這個問題,但我會更聚焦在 AI 如何呈現在我們的產品中、以及如何與客戶互動,而不是公司端(corporate side)的 AI。

  • And so if -- when we look at AI, it's like any other product, and it's really through the lens of the Quintuple Aim and will it advance outcomes and reduce variation, improve certain patient experiences, lower total cost advanced access for patients around the globe. And we believe, yes, that AI will be a contributor to moving the Quintuple Aim forward.

    因此,當我們看待 AI 時,它就像任何其他產品一樣,我們會透過「五重目標(Quintuple Aim)」的視角來評估:它是否能改善臨床結果並降低差異、提升特定的病患體驗、降低總成本,並為全球患者提供更進一步的可近性。我們相信答案是肯定的,AI 將有助於推動五重目標向前。

  • And our approach here is what we've described in the past. And it's really to build kind of this layered capabilities. And it starts with high-quality data -- and that data will exist in video data from surgeries. It will exist in robotic data streams like kinematic data and force data.

    而我們在這方面的做法如同過去所描述的。核心是建立一種分層式的能力。起點是高品質資料——這些資料會存在於手術的影像(video)資料中。也會存在於機器人資料串流中,例如運動學(kinematic)資料與力覺(force)資料。

  • It will exist in connected electronic medical records, where we're working with customers to do so. And once we have that high-quality data set, then the job of our AI and our data scientists is to turn that into meaningful insights.

    它將存在於互聯的電子病歷中,我們正與客戶合作來實現這一點。而一旦我們擁有那套高品質資料集,我們的 AI 與資料科學家的工作就是把它轉化為有意義的洞見。

  • And once we have those, I think the critical part here is how do we deliver those to the customer. and it has to be in a consumable fashion, it has to be at the right time in the moment that enters to the customer.

    而一旦我們有了這些,我認為這裡的關鍵在於我們要如何把它們交付給客戶。它必須以可被消化的形式呈現,必須在正確的時間點、在客戶所處的當下情境中送達。

  • So there are, I think, ways in which this will show up to the customer. Some will be as operational guidance and assistance as they look at their hospital robotic program and want to increase efficiencies or understand costs. Some of it may show up in the learning surgeon and/or a care team.

    因此,我認為有幾種方式會讓客戶感受到這些成果。其中一部分會以營運指引與協助的形式呈現,當他們檢視其醫院的機器人手術計畫並希望提升效率或了解成本時。其中一部分可能會出現在外科醫師學習與/或照護團隊上。

  • But a lot of it will show up in the operating room, and I think show up in the surgery itself. And an example of this kind of first phase might be AI-enabled anatomy identification where you can see AI showing critical structures in the surgical field showing tissue planes to help assist the surgeon.

    但其中很大一部分會出現在手術室裡,我認為也會直接出現在手術本身。第一階段的一個例子可能是 AI 輔助的解剖辨識,讓你看到 AI 在手術視野中標示關鍵結構、顯示組織層面,以協助外科醫師。

  • Then, over time, what we expect is that many of those same foundations that are being established and built in kind of that first phase, if you will, will support more advanced assistance around augmented dexterity and it will include -- likely include aspects of automation.

    接著,隨著時間推進,我們預期在第一階段所建立與打造的許多相同基礎,將支援更進階的協助,例如增強靈巧度,並且——很可能——會包含自動化的部分。

  • There, an example might be helping to control the camera as the surgeon is focused on the procedure. And so throughout this, every step, it's about clinical value, of course, and it's about safety and reliability and not just doing this in a one-off but doing this in a scaled fashion. And so if I look at that as the layer that we're progressing through and I'd look to see where -- how do we sit, how do we exist within the AI ecosystem and how are we differentiated?

    例如,可能是協助控制攝影機,讓外科醫師能專注於手術流程。因此在整個過程中,每一步都關乎臨床價值,當然也關乎安全性與可靠性;而且不是一次性的嘗試,而是要以可規模化的方式來做。所以如果我把這視為我們正在推進的一個層次,我會去看——我們在 AI 生態系中如何定位、如何存在,以及我們如何形成差異化?

  • I think part of that differentiation is around the installed base of systems that we have out there, including about the 1,500 da Vinci 5 systems, the 3 million and more procedures that are being done on an annual basis. And I believe that gives us the foundation to strengthen the differentiation over the next three to five years.

    我認為差異化的一部分來自於我們已安裝的系統基礎,包括約 1,500 台 da Vinci 5 系統,以及每年進行的 300 萬例以上手術。我相信這為我們在未來三到五年強化差異化提供了基礎。

  • If you look at the industry and you say, what is broadly available, broadly available to everyone, it's things like edge and cloud compute, the math that underscores much of this, some of the training algorithms. Our advantage, we believe, why is in the unique data sets that are available to us today through something like force feedback and will be increasingly available to us as we add capability to da Vinci 5.

    如果你看整個產業並問:什麼是廣泛可得、人人都能取得的?那就是邊緣與雲端運算、支撐其中多數內容的數學基礎、以及部分訓練演算法等。我們認為我們的優勢在於:透過例如力回饋等方式,我們今天就能取得獨特的資料集;而且隨著我們為 da Vinci 5 增加能力,這些資料將愈來愈多。

  • And so all of that together creates the flywheel. It's a flywheel that starts with data, insights, actions, advancing the quintuple the flywheel spins it becomes that virtuous cycle. And we have the teams focused on it, and we are investing to advance this in the future and look forward to updating you along the journey.

    因此,這一切共同形成了飛輪效應。這個飛輪從資料開始,產生洞見、帶來行動、推進「五重目標(Quintuple Aim)」;飛輪轉得越快,就越形成那個良性循環。我們有團隊專注於此,也正在投資以推動未來的進展,並期待在這段旅程中持續向各位更新。

  • Travis Steed - Analyst

    Travis Steed - Analyst

  • That's exciting. Can't wait. Maybe my follow-up question, Jamie, on margin. You highlighted some macro stuff, but still raised gross margin 50 basis points and tariffs only came down 20 basis points. So I guess the contribution margin of DV5 comparable excise, a nice positive for margins.

    這很令人振奮。迫不及待。我可能有個追問,Jamie,關於毛利率。你提到一些總體因素,但仍把毛利率上調 50 個基點,而關稅只下降了 20 個基點。所以我想,DV5 的貢獻毛利率可比於消費稅(excise),對毛利率是個不錯的正面因素。

  • But kind of curious kind of what you saw in the macro and what you kind of baked in on that front? And any color on kind of what percent of COGS you'd call chips and exposure to oil and resin?

    但我有點好奇,你在總體環境上看到了什麼,以及你在這方面納入了哪些假設?另外,能否補充一下:在銷貨成本(COGS)中,你會把多少比例歸類為晶片,以及對油價與樹脂的曝險?

  • Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

    Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

  • Yes. I'd just say for oil prices and the derivative impact that has on input prices and logistics costs and memory, based on what we know today, in the gross margin guidance, it has an impact, but it's relatively small. I think what you see in Q1, in particular, is relatively significant leverage from the 23% revenue growth and a really nice contribution from the product cost reductions that we've described. So the macro is having an impact. And obviously, we're watching it carefully and you also have to watch the potential supply constraints.

    是的。我只能說,就油價以及其對投入成本與物流成本、以及記憶體的衍生影響而言,基於我們目前所知,在毛利率指引中確實有影響,但相對較小。我認為你在第一季特別看到的是:23% 的營收成長帶來相當顯著的槓桿效應,以及我們先前所描述的產品成本降低帶來非常好的貢獻。所以總體環境確實在產生影響。而且很明顯,我們正密切關注,同時也必須留意潛在的供應限制。

  • But the macro is baked in and relatively small, just given the components of our product costs.

    但總體因素已納入考量,而且相對較小,主要是因為我們產品成本的構成。

  • Travis Steed - Analyst

    Travis Steed - Analyst

  • Great. Thanks a lot.

    很好。非常感謝。

  • David Rosa - Chief Executive Officer, Director

    David Rosa - Chief Executive Officer, Director

  • So Travis, real quick, you had asked about ROSE and Quintuple Aim and just some color there. So both our known technologies. And the time lines are more short term, but they won't be this year. We do believe that they are bringing a truly significant differentiated value to the lung cancer diagnosis, detection and diagnosis journey and expect to share that value with customers. And so as that gets closer, we'll let you know more about it.

    Travis,很快補充一下,你剛才問到 ROSE 和「五重目標(Quintuple Aim)」以及相關的一些說明。這兩項都是我們已知的技術。時間線偏短期,但不會在今年。我們確實相信,它們能為肺癌的偵測與診斷流程帶來真正顯著且具差異化的價值,並預期會把這些價值與客戶分享。因此,等到更接近時,我們會再提供更多資訊。

  • Travis Steed - Analyst

    Travis Steed - Analyst

  • Great. Thanks a lot.

    很好。非常感謝。

  • Operator

    Operator

  • Larry Biegelsen, Wells Fargo.

    Larry Biegelsen,富國銀行(Wells Fargo)。

  • Lawrence Biegelsen - Analyst

    Lawrence Biegelsen - Analyst

  • All right, thanks for taking the question. Congrats on a good start to the year here. I had one on procedures, and then I had one follow-up for Jamie. So I'd love to hear you talk about the appendectomy opportunity. It looks like about $300,000 per year. It's one of the first steps I've heard you call that out on an earnings call, $300,000 per year in the US.

    好的,謝謝讓我提問。恭喜今年有個不錯的開局。我有一個關於手術量(procedures)問題,然後還有一個給 Jamie 的追問。我很想聽你談談闌尾切除術(appendectomy)的機會。看起來大約是每年 30 萬例。這是我第一次聽到你在財報電話會議上提到這點——在美國每年 30 萬例。

  • And if you could size the incremental Japan opportunity from those new procedures. That would be great. And I had one follow-up.

    另外,如果你能估算日本因那些新增術式所帶來的增量機會規模,也會很棒。謝謝。我還有一個追問。

  • Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

    Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

  • Yes. We haven't sized appendectomy yet. I think there's a question of what makes sense in terms of the robotic portion of that overall TAM because we're so early in appendectomy, we're still kind of working through internally on what we think is the right opportunity. We called out the kind of emerging evidence on clinical outcomes just because over the quarter, actually, we've had a couple of engagements with surgeons that have kind of done work in their own institutions. And we saw several of those come together.

    是的。我們尚未對闌尾切除術做規模估算。我認為問題在於:就整體可服務市場(TAM)而言,其中機器人手術的占比應該是多少才合理;因為我們在闌尾切除術上仍非常早期,內部仍在推進並評估我們認為合適的機會大小。我們之所以提到臨床結果方面的新興證據,是因為在這一季期間,實際上我們與幾位外科醫師有過一些交流,他們在各自機構內做了一些研究工作。我們看到其中幾項結果匯聚在一起。

  • And across the set of functional outcomes in the work that they did, da Vinci was better on all comparison points, which we thought was encouraging. We'd like to see that show up in clinical studies that have larger data sets in terms of number of patients, but we think that's super interesting for what is typically a relatively quick procedure with relatively low reimbursements.

    而在他們所做工作的一系列功能性結果指標上,da Vinci 在所有比較點上都更好,我們覺得這令人鼓舞。我們也希望在擁有更大資料集、更多病患數的臨床研究中看到同樣結果,但我們認為這對於一項通常相對快速、且給付相對較低的手術而言,非常有意思。

  • Lawrence Biegelsen - Analyst

    Lawrence Biegelsen - Analyst

  • And Japan?

    那日本呢?

  • Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

    Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

  • On Japan, I think we noted MHLW added reimbursement coverage for seven procedures across a couple of different categories. The largest of those is bilateral inguinal hernia repair. Reimbursement there is roughly $1,500 per procedure. I think in aggregate, it's too early for us to size the incremental procedure opportunity in Japan. But the impact is relatively modest and like in prior periods where we've had incremental reimbursement, it will take time to develop

    關於日本,我想我們提到過厚生勞動省(MHLW)在幾個不同類別中,新增了 7 項術式的給付涵蓋。其中最大的一項是雙側腹股溝疝氣修補術。該項給付約為每例 1,500 美元。我認為整體而言,我們現在要估算日本增量手術量的機會還太早。但其影響相對溫和,而且如同過去我們獲得新增給付的期間一樣,仍需要時間來發展。

  • Lawrence Biegelsen - Analyst

    Lawrence Biegelsen - Analyst

  • Jamie, I love if you flesh out more what you meant by innovation-led revenue growth. That's the first time I've heard you talk about that. Is there any way to frame how much faster revenues will grow versus procedures. In Q1, it was obviously 23% versus 17%. Do you expect that delta to increase going forward?

    Jamie,我很希望你能更詳細說明你所指的「以創新帶動的營收成長」是什麼意思。這是我第一次聽你談到這個。有沒有辦法用一個框架來說明,營收成長相較於手術量(procedures)會快多少?在第一季,顯然是23%對17%。你預期這個差距(delta)未來會擴大嗎?

  • Maybe just talk about the implications of this innovation revenue growth.

    也許可以談談這種創新帶動營收成長的意涵。

  • Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

    Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

  • Yes. I really felt like it was worth describing because if we look back at last year, even revenue growth was 21%. And obviously, procedure growth was also lower than that last year. And then you see the numbers in Q1. The business framing we have is kind of what I described as a push and pull.

    好的。我真的覺得值得描述一下,因為如果回頭看去年,營收成長也有21%。而且很明顯,去年手術量成長也低於那個數字。然後你再看第一季的數字。我們對業務的框架,有點像我所描述的「推與拉」。

  • We're very conscious about deploying our R&D to places where we can be differentiated and make a difference on the quintuple that's integrated in how we make R&D deployment decisions. And so where you can be differentiated and make a resale difference for customers, then -- and create value for them, then you get to share in that value in the form of on the intuitive side, accretive pricing or incremental pricing. And we see that in da Vinci 5, you see that actually in SP I&A and there are other areas where we have that opportunity.

    我們非常有意識地把研發資源投入到我們能夠差異化、並且能在「五重目標(quintuple)」上帶來改變的領域;這也整合在我們做研發資源配置決策的方式之中。因此,當你能夠差異化、為客戶帶來真正的轉售差異(resale difference),並為他們創造價值時,你就能以直覺(Intuitive)這一端的方式,透過增益性定價或額外定價來分享那份價值。我們在da Vinci 5上看得到這點,在SP I&A上其實也看得到,還有其他一些領域我們也有這樣的機會。

  • On the other side of it, if you look at the totality of our business, there, of course, are procedures and geographies that are more cost sensitive. And so we also then look for -- as we work on bringing our costs down, particularly our manufacturing and product costs, we also look for opportunities to then share that cost savings with our customers because they have the economic or cost sensitivity.

    另一方面,如果你看我們業務的整體,當然也有一些手術類別與地區對成本更敏感。因此,當我們致力於降低成本、特別是製造與產品成本時,我們也會尋找機會把這些成本節省與客戶分享,因為他們在經濟面或成本面更敏感。

  • And we do that particularly in mind with what can be the elasticity response when it's cost sensitive. And so we work on both of those. And therefore, that creates a mix dynamic between the two. In terms of like how long does it sustain?

    我們在做這件事時,特別會考量在成本敏感情境下可能出現的需求彈性反應(elasticity response)。所以我們兩邊都在做。因此,兩者之間就會形成一種組合(mix)動態。至於像「能維持多久?」

  • I don't think I want to get into that just because we don't guide revenue, it's really our attempt to just describe what's happened in recent periods with respect to the difference between revenue growth and procedure growth. And I think we're just reemphasizing the fact that innovation is critical to our success.

    我不認為我想深入談這個,因為我們不提供營收指引;我們主要是嘗試描述近期期間中,營收成長與手術量成長之間差異所發生的情況。而我想我們只是再次強調:創新對我們的成功至關重要。

  • Robert Marcus - Analyst

    Robert Marcus - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Robbie Marcus, JPMorgan.

    Robbie Marcus,摩根大通(JPMorgan)。

  • Robert Marcus - Analyst

    Robert Marcus - Analyst

  • Oh, great. Thanks for taking the questions. I'll add my congratulations on a really nice quarter as well. Two for me. First, the utilization continues to just be really impressive, especially with the after hours metrics and the utilization improvement on da Vinci 5, which is now becoming a pretty substantial part of the installed base.

    太好了。謝謝讓我提問。我也要恭喜你們交出非常漂亮的一季。我有兩個問題。第一,使用率(utilization)持續非常亮眼,尤其是下班後(after hours)的指標,以及da Vinci 5的使用率提升;而da Vinci 5現在已經成為裝機基礎中相當重要的一部分。

  • I was hoping you could just add a little more color there in terms of how much more is there to go? Because I think everyone knows that utilization and procedure volume growth ultimately is what drives placements.

    我希望你能再補充一些細節:還有多少提升空間?因為我想大家都知道,使用率與手術量成長最終才是推動裝機(placements)的因素。

  • So how much more is there to go? And how do you think about that translating into unit growth down the road? How much and when, if you're willing to quantify? Thanks.

    所以,還能提升多少?你怎麼看這會如何轉化為未來的出貨台數成長(unit growth)?如果你願意量化的話,是多少、以及在什麼時點?謝謝。

  • Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

    Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

  • That's -- in some regards, that's the impossible question to answer in the following sense, Robbie. It really -- you have to be aware of the averages, and you have to look at it by market in terms of where is the distribution of utilization within any given market, what's the mix of systems they have in any given market. From a macro perspective, we are strategically aligned with customers that we want to increase robotic throughput because we think that serves them well economically and is good for Intuitive long term. So it's a difficult question to answer.

    Robbie,從某些角度來看,這是一個不可能回答的問題,原因如下。你必須留意平均值的侷限,並且要按市場來看:在任何一個市場內,使用率的分布在哪裡、該市場的系統組合是什麼。從宏觀角度,我們在策略上與客戶一致,希望提高機器人手術的吞吐量(robotic throughput),因為我們認為這在經濟上對他們有利,且對Intuitive的長期發展也有利。所以這確實很難回答。

  • There are markets where there's obviously room to improve utilization such as Japan and some of the European markets. In the US., I think utilization growth will mostly be driven by the rate by which the entire installed base in the US switches over to da Vinci 5, which we think structurally has the ability given its feature set to run higher levels of utilization in Xi. For us, we'd like to keep utilization growth going because we think it's super critical and differentiates us, I think, from competitors also. But I don't think we have the ability to call how long it goes and what the derivative impact is.

    有些市場顯然還有提升使用率的空間,例如日本以及部分歐洲市場。在美國,我認為使用率成長主要會由整個美國裝機基礎切換到da Vinci 5的速度所驅動;我們認為,從結構上來看,da Vinci 5憑藉其功能組合,相較於Xi能夠支撐更高的使用率水準。對我們而言,我們希望使用率成長能持續,因為我們認為這非常關鍵,也讓我們與競爭對手形成差異化。但我不認為我們有能力去預測它會持續多久,以及其衍生影響(derivative impact)是什麼。

  • Robert Marcus - Analyst

    Robert Marcus - Analyst

  • I know it's a hard question. That's why I'm asking you. I'm hoping you could do my job for me a little bit. Maybe just a follow-up. We have more and more competitors trying to enter the market here, some in the US from big surgical competitors, some in China, others in Europe, you now have the opportunity to offer a tiered pricing strategy with refurbished Xis. It'd be great just to get a refresh on how you're thinking about global competition at different price points in different markets and how you're feeling about your positioning there? Thanks a lot.

    我知道這很難。所以我才問你。我希望你能多少幫我做一點我的工作。也許再追問一下。現在有越來越多競爭者想進入市場:有些是在美國、來自大型外科競爭對手;有些在中國;還有其他在歐洲。你們現在也有機會透過翻新Xi提供分層(tiered)的定價策略。很希望你能更新一下:你們如何看待在不同市場、不同價位帶的全球競爭?以及你們對自身定位的感受如何?非常感謝。

  • David Rosa - Chief Executive Officer, Director

    David Rosa - Chief Executive Officer, Director

  • Yes, Robbie. So I think we've -- competition is about, I think, meeting the needs of the customer at the right price point. And so it's really about the value that they're going to obtain for getting a robotic program established and treating patients and getting to great outcomes. And so what we know is that the basis of competition, we are wanting to make sure that people look at it not as the kind of the price you pay for the robot and the fact that now you have it in one of your ORs, but it's really the value of your program. How are patients being treated?

    好的,Robbie。所以我認為——競爭的核心在於,以合適的價格點滿足客戶需求。因此,重點在於:他們建立機器人手術計畫、治療病患並取得優異結果時,能獲得什麼價值。我們所知道的是,競爭的基礎,我們希望確保大家看的不是「你為機器人付了多少錢、以及你現在把它放在某一間手術室(OR)裡」這種角度,而是你的計畫本身的價值。病患是如何被治療的?

  • Are you seeing the outcome improvements? Are you seeing a shift in the mix of open surgery to minimally invasive robotic procedures that you expected in any of the other strategic initiatives that a given customer might have? And so that's where and how we want to ensure that we are entering the conversations with customers and helping educate them around the globe about the questions they should be asking what kind of data should they be looking for as they engage one or more robotic competitors from around the globe.

    你是否看到治療結果的改善?你是否看到如預期般,從開放式手術轉向微創機器人手術的組合變化?以及是否符合某個客戶可能有的其他策略性倡議?因此,這就是我們希望如何、以及在哪裡與客戶展開對話:協助全球客戶理解,他們在接觸來自全球的一個或多個機器人競爭者時,應該問哪些問題、應該看哪些資料。

  • And when it comes to those conversations and the data that are shared, I expect with our portfolio and now with XiR added, that will be a strong choice to lead in those value because of the demonstrated clinical output, the reliability of our systems, our ecosystem of services and training that can support them on their journey. And so that is, I think, the high-level picture of how we compete globally.

    而在這些對話以及所分享的資料層面,我預期憑藉我們的產品組合、以及現在加入的XiR,我們會是很強的選擇,能在價值層面領先,因為我們已被證實的臨床產出、系統可靠性,以及能在他們旅程中提供支援的服務與訓練生態系。所以我認為,這就是我們在全球競爭的高層次圖像。

  • Jamie, anything else you may want to add to that.

    Jamie,你還有什麼想補充的嗎?

  • Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

    Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

  • I would just say we're still selling X, and actually, we sold 41 X systems in the quarter, 34 refurbished Xis. And then, of course, we have DV5, I think the segmentation there is really appealing. And in some sense, is a competitive advantage for us to be able to tier feature the capability and economics for various segments of our customers. The refurbished Xi like Dave said, if I'd just say it again, that is a very capable product. It has the full complete suite in the ecosystem and the economics for customers are really attractive.

    我只想說,我們仍在銷售X,事實上本季我們賣出了41台X系統,以及34台翻新Xi。然後當然我們還有DV5;我認為那樣的市場區隔(segmentation)非常有吸引力。某種程度上,能夠針對不同客戶區隔,提供分層的功能、能力與經濟性,對我們而言是一項競爭優勢。翻新Xi如Dave所說——我再說一次——那是一個非常有能力的產品。它具備生態系中完整的全套組合,且對客戶而言其經濟性非常具吸引力。

  • And so I think that's been a great kind of addition to the system portfolio.

    因此我認為,這確實是對系統產品組合的一項很好的補充。

  • Robert Marcus - Analyst

    Robert Marcus - Analyst

  • Thanks a lot. Appreciate it.

    非常感謝。感激不盡。

  • Operator

    Operator

  • Rick Wise, Stifel.

    Rick Wise,Stifel。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Good afternoon, everybody. Sorry for my scratchy voice here. One specific question for Jamie and then a bigger picture question for you, Dave. Jamie, just help us, if you could better understand what dynamics internationally drove I&A at double the rate of procedure growth. I mean it's -- obviously, it's a big delta of 40% OUS I&A versus 19% OUS procedure growth. Was there anything onetime there or country specific?

    各位下午好。抱歉我這邊嗓音有點沙啞。我先問 Jamie 一個比較具體的問題,然後再問你一個更宏觀的問題,Dave。Jamie,如果可以的話,請幫我們更好地理解:國際市場有哪些動態因素,讓 I&A 的成長速度達到手術量成長的兩倍。我的意思是——很明顯,OUS I&A 成長 40%,而 OUS 手術量成長 19%,差距很大。這裡面有任何一次性因素或特定國家的因素嗎?

  • And is this dynamic -- should we imagine this dynamic continues? Thank you.

    另外,這種動態——我們是否應該預期這種動態會持續?謝謝。

  • Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

    Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

  • I have not looked at that deeply for OUS specifically, Rick. I do think the customer ordering pattern is likely a good chunk of that because all of our distributors obviously are international, and they can be pretty lumpy in terms of their kind of ordering patterns they can place orders in the quarter for several quarters. So I'd imagine that the greatest impact is that. And I think given the strong capital placements, we probably had a bunch of stocking orders that also benefited Q1. And finally, there is a benefit from FX.

    Rick,就 OUS 這部分我沒有特別深入去看。但我確實認為,客戶的下單模式很可能是其中相當大的一部分原因,因為我們所有的經銷商顯然都在國際市場,而且他們的下單節奏可能相當不均勻——他們可能在某一季下單,涵蓋接下來好幾季的需求。所以我想最大的影響應該是這個。另外,我認為在資本設備裝機表現強勁的情況下,我們可能也有一批補庫存訂單,這也讓第一季受益。最後,匯率也帶來了一些助益。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Got you. All right, Jamie. Dave, for you, just as we get ready for some upcoming robotic meetings and I reflect on some of the topics that are going to be discussed and presented. I was hoping you maybe would sort of step back and looking longer term, talk about a couple of initiatives that others are focused on and to what degree is this important to Intuitive Surgical?

    了解。好,Jamie。Dave,接下來我想問你:我們正準備參加一些即將到來的機器人相關會議,我回想一些將被討論與發表的主題。我希望你能稍微退一步、以更長期的角度,談談其他人正在關注的幾項倡議,以及這些對 Intuitive Surgical 的重要性到什麼程度?

  • Like telesurgery robotics, so we saw the first promote procedure done recently, the value of robotics to stroke or a minimally invasive cardiovascular disease.And just again, at the highest level, your interest or passion or focus on areas like that, that might be future drivers of growth for Intuitive.

    例如遠距手術機器人,我們最近看到第一例推廣手術(promote procedure)完成;以及機器人對中風或微創心血管疾病的價值。再一次,從最高層級來看,你對這些領域的興趣、熱情或投入重點是什麼?它們是否可能成為 Intuitive 未來的成長驅動因素?

  • Thank you both.

    也謝謝你們兩位。

  • David Rosa - Chief Executive Officer, Director

    David Rosa - Chief Executive Officer, Director

  • I really appreciate the question, Rick. If I stand back and I think about adding incremental capabilities to our ecosystem. It is about where on, number one, we can drive the Quintuple Aim. Number two, whatever it is, we think will be better in our hands. And so to -- for example, some of the things that you called out on telesurgery, I actually -- I really believe deeply in the collaboration capabilities of these telestration, telecollaboration tools.

    Rick,我非常感謝這個問題。如果我退一步來看,思考為我們的生態系增加增量能力。第一,是看我們能在哪些方面推動「五重目標(Quintuple Aim)」。第二,不管是什麼,我們認為在我們手上能做得更好。因此——例如你提到的遠距手術,我其實——我非常深信這些標註示教(telestration)、遠距協作工具的協作能力。

  • And we are seeing some pretty rapid utilization of our current platform with my Intuitive Plus, and we're seeing thousands of use cases a month. And so that is, I think, demonstrating stickiness and value with our customers.

    而且我們看到目前平台搭配 my Intuitive Plus 的使用率提升得相當快,每個月有數千個使用案例。因此我認為,這正在向客戶展現黏著度與價值。

  • As we expand those capabilities and it will include telesurgery in the future, that is on our road map. We expect that to be a subset of those use cases. And I -- just yesterday, I was with a customer here and we were speaking to their expectation of how telesurgery will be deployed within their IDN, within their small set of hospitals.

    隨著我們擴展這些能力,未來也會包含遠距手術——這在我們的路線圖上。我們預期那會是這些使用案例中的一個子集合。而且——就在昨天,我和這裡的一位客戶在一起,我們談到他們預期遠距手術將如何在其整合式醫療網(IDN)內、在其少數幾家醫院中部署。

  • And I think there's real value there, though we do believe that a majority of the use cases when tele-collaboration is warranted will likely be served by existing tools with telestration and audio/video interactions. And it will, if you will, kind of escalate to telesurgery in certain use cases.

    我認為那裡確實有實質價值,儘管我們也相信:在需要遠距協作的大多數使用情境中,現有工具(包含標註示教以及音訊/視訊互動)很可能就能滿足。而在某些使用情境下,才會進一步「升級」到遠距手術。

  • So I do think that's an important part of our future in what customers we'll find value in.

    所以我確實認為,這是我們未來的重要一環,也是客戶會覺得有價值的部分。

  • Recently, semi recently, we've announced kind of our investment into cardiac in cardiac surgery. And there, again, I believe that there's going to be a set of patients who can benefit from minimally invasive cardiac surgery and a set of patients who will benefit from percutaneous transcatheter approaches.

    最近——算是半近期——我們宣布了對心臟、心臟手術領域的投資。在那裡,同樣地,我相信會有一部分病患能從微創心臟手術中受益,也會有一部分病患能從經皮、經導管的介入方式中受益。

  • And the evidence shows that, in some cases, surgery is better, and in some cases, an interventional approach is better. And when surgery is warranted, then I think the investments we're making in capabilities of da Vinci 5 and our investments in training, in particular, will pay dividends and have an opportunity for surgeons to treat patients with a very minimally invasive cardiac approach to their disease.

    而證據顯示,在某些情況下,手術更好;在某些情況下,介入式治療更好。當需要手術時,我認為我們在 da Vinci 5 能力上的投資,以及我們在訓練(尤其是訓練)上的投資,將帶來回報,並讓外科醫師有機會以非常微創的心臟手術方式來治療病患的疾病。

  • And there are others, you mentioned stroke. That is an interesting area. But there are plenty of areas that I think about in terms of adding capability and procedures and value to Intuitive and to the patients that our customers serve. One of the trends over the year that I've been just kind of fascinated by is how surgeons take the core capabilities of a platform like da Vinci and apply them into areas that we didn't envision that it wasn't an area that we investigated and that's been repeated over and over. And that -- and I believe, with da Vinci 5 capabilities that exist today and as we add more in the future, we're going to see that cycle continue.

    還有其他領域,你提到中風。那是一個有趣的領域。但我想到的、能為 Intuitive 以及我們客戶所服務的病患增加能力、手術項目與價值的領域其實很多。過去一年讓我相當著迷的一個趨勢是:外科醫師如何把像 da Vinci 這樣的平台核心能力,應用到我們未曾預見、也不是我們曾研究過的領域,而且這樣的情況一再重複發生。而且——我相信,憑藉 da Vinci 5 目前已具備的能力,以及我們未來再加入更多能力,我們會看到這個循環持續下去。

  • And we're going to see surgeons and we're seeing it already, say, Hey, we think there is value in these areas that aren't currently served. And so I'm excited by some of those opportunities. We'll do the work to see if indeed there's true value there, and it can be scaled and repeatable and teachable. But it's an area that I look forward to updating you along the way.

    我們也會看到外科醫師——而且我們已經在看到——說:嘿,我們認為在一些目前尚未被服務的領域存在價值。因此我對其中一些機會感到興奮。我們會做功課去確認那裡是否真的有價值,並且能夠規模化、可重複、可教學。但這是我期待在過程中持續向各位更新的領域。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Great. Thank you, Dave.

    很好。謝謝你,Dave。

  • Operator

    Operator

  • David Roman, Goldman Sachs.

    David Roman,高盛。

  • David Roman - Analyst

    David Roman - Analyst

  • Thank you. I appreciate your taking the question here. Maybe you could start on SP. And it looks like a lot of pieces are coming together here to support.

    謝謝。感謝你在這裡回答問題。也許你可以先從 SP 談起。看起來有很多要素正在到位以提供支撐。

  • Further adoption of that technology, whether that's additional clearances from a procedure standpoint or additional instrumentation. Maybe just give us a sense of where we are in bringing SP to a point where that adoption curve can accelerate, whereby that becomes a more just meaningful percentage of places. And I guess if you could also contextualize that, is that additive to the overall addressable procedure market, or does it become a choice of a typical DV5 procedure or SP?

    以進一步推動該技術的採用,不論是從手術適應症角度取得更多核准,或是增加更多器械。也許請你讓我們了解一下:我們目前在把 SP 推進到一個採用曲線可以加速的階段,進展到哪裡?也就是說,讓它成為更具意義的裝機占比。另外如果可以也請你幫我們放在脈絡中:這是對整體可觸及手術市場(TAM)的增量擴張,還是會變成典型 DV5 手術與 SP 之間的選擇?

  • Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

    Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

  • Yes. I guess I would say if you look at the kind of procedure growth over the last year or so, it's been strong, 68% this last quarter. And that strength has been in part driven by additional geographical clearances and additional procedure clearances, particularly in the US. And so I think that, that then continues over some period. It's not that it suddenly inflects and accelerates from where it is.

    是的。我想我會這麼說:如果你看過去一年左右的手術量成長,其實相當強勁,上一季達到 68%。而這股強勁部分是由更多地理區域的核准以及更多手術適應症的核准所帶動,尤其是在美國。因此我認為,這樣的趨勢會在一段時間內延續。並不是說它會突然出現拐點,然後在目前的基礎上加速。

  • I think we continue that kind of progression on some reasonable pace. If you look at the question of long term, what are the incremental opportunities that are different from multiple, the multiple is not going to serve and therefore an effect of TAM expanding. I think those opportunities exist. Nipple-sparing mastectomy is a good example of that. And obviously, that's in an early stage. You have some work being done to see if SP is better than alternatives, including multiple.

    我認為我們會以合理的步調持續這樣的進展。如果你從長期的角度來看,哪些增量機會是不同於多孔(multiport)的——多孔不會適用,因此會帶來TAM擴大的效果。我認為那些機會確實存在。保留乳頭的乳房切除術(nipple-sparing mastectomy)就是一個很好的例子。而且很明顯,這仍處於早期階段。我們正在進行一些工作,以評估SP是否優於替代方案,包括多孔。

  • And of course, that's been largely in exchange between one stream or one set of procedures that we have to another. There's work in our labs that's super interesting for additional disease states that aren't served today the TAM expanding is too early for us to discuss because our current focus is on the opportunity we have.

    當然,這在很大程度上是我們從一條產品線或一組既有手術,轉換到另一條產品線或另一組手術之間的替代。我們實驗室裡也有一些非常有趣的研究,針對目前尚未被服務的其他疾病狀態;至於TAM擴大,現在談還太早,因為我們目前的重點在於我們手上既有的機會。

  • We have still a long way to go in each of the markets where we are cleared and for the new indications that we've added. And so like the next year or two is -- that's where our focus is. But I think the long-term opportunity for SP is perhaps a little underestimated.

    在我們已獲核准的各個市場,以及我們新增的適應症方面,我們仍有很長的路要走。因此,接下來一到兩年——那就是我們的重點所在。但我認為,從長期來看,SP的機會可能被低估了一些。

  • David Roman - Analyst

    David Roman - Analyst

  • That's helpful. And I appreciate. It's hard to get into all the detail on a call like this regarding just your OUS strategy given the number of different geographies and moving pieces. But maybe just at a high level, you could help us think about the number of actions you've taken here. You acquired distributors in Europe.

    這很有幫助。也謝謝你。在像這樣的電話會議上,要把你們的美國以外(OUS)策略的所有細節都講清楚確實很難,因為涉及不同地理區域與許多變動因素。但也許在較高層次上,你可以幫我們理解你們在這裡採取的幾項行動。你們在歐洲收購了經銷商。

  • You have the IR opportunity. You have a joint venture in China to go after that market. But how are you prioritizing markets outside the US? And what is, broadly speaking, the strategy here just to ensure competitiveness as new lower-cost entrants approach the market, but also contrasted with things like favorable reimbursement clearances in the UK, which occurred last year. Maybe just help think about how OUS evolves here a little bit over the course of '26 and how that contributes to your forward outlook here.

    你們有IR的機會。你們在中國也有合資企業來開拓那個市場。但你們如何在美國以外的市場之間排定優先順序?而整體而言,這裡的策略是什麼——一方面要確保在新的低成本競爭者進入市場時仍具競爭力,另一方面也要對照像英國這類在去年取得有利給付核准的情況。也許請你協助我們思考,OUS在2026年期間會如何演進,以及這如何對你們的前瞻展望做出貢獻。

  • David Rosa - Chief Executive Officer, Director

    David Rosa - Chief Executive Officer, Director

  • David, for me, you sort of answered your own question, I think. It is all of the above, right? Our investments start with the people we have in the region and to ensure that they understand deeply are well trained, of course. The investments we have in our products, including an expanding system portfolio, ensuring that the procedures that are being served in that geography have the right rest of the ecosystem cleared in that geography.

    David,就我而言,我覺得你某種程度上已經回答了你自己的問題。就是以上皆是,對吧?我們的投資首先從我們在當地的人員開始,並確保他們對相關內容有深刻理解、且受過良好訓練,當然。我們也投資在產品上,包括擴大的系統產品組合,並確保在該地理區域所服務的手術,其所需的其餘生態系也已在該地理區域取得核准。

  • That's another piece of the puzzle as we continue to innovate and bring new products to the market, we want to ensure those are available as well. So there are regulatory pathways. And so we have the portfolio of products that are required in a given geography.

    這也是拼圖中的另一塊:當我們持續創新並將新產品推向市場時,我們也希望確保這些產品同樣可取得。因此會涉及法規核准途徑。也就是說,我們會在特定地理區域具備所需的產品組合。

  • Then, what we want to do is ensure to the very best of our ability that they are priced appropriately for the value they bring. And so we have broad economic programs and pricing that we're able to tailor to the market. But what we want to do, and I mentioned this briefly before, is we want to ensure that the value that's being realized is able to be articulated and substantiated in a given geography. That is not just all about price.

    接著,我們希望盡最大努力確保定價能反映其帶來的價值。因此我們有廣泛的經濟方案與定價機制,能夠依市場進行調整。但我們想做的——我之前也簡要提過——是確保在特定地理區域中,所實現的價值能被清楚表達並被證實。這不只是價格的問題。

  • And so that's a piece of the market access effort that goes into ensuring our customers themselves understand the value, but also that the reimbursement in government agencies that drive the overall economics of a given country also understand the value.

    因此,這也是市場准入工作的一部分:確保我們的客戶本身理解其價值,同時也讓主導一個國家整體經濟面的政府機關與給付單位理解其價值。

  • And that's a multiyear journey. So you get it from both sides, kind of the products and pricing, but also the value being realized by both customers and the government. And that is a geography by geography amount of work and that's years in the making around the globe.

    而這是一段跨多年的旅程。所以你會從兩個面向同時推進:產品與定價,以及客戶與政府雙方對所實現價值的認知。而這需要逐一地理區域地投入工作,並且是在全球範圍內多年累積而成。

  • Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

    Jamie Samath - Executive Vice President, Chief Financial Officer, Head of Business Technology

  • Maybe I'd just add. In each of the markets, we take a localized approach to how we engage what our strategy is there and each of those markets has a strict strategic plan, and that results in us investing differentially in each of those markets.

    我再補充一點。在每個市場,我們都採取在地化的方式來互動與制定策略;每個市場都有嚴謹的策略計畫,因此我們會在各市場採取差異化的投資。

  • For OUS, as you've seen, we'll go direct in markets already where we think the opportunity makes sense for us. And there may be instances where we start to look in large markets some localized manufacturing, which is becoming increasingly important for some of those markets.

    就OUS而言,如你所見,我們會在我們認為機會對我們有意義的市場採取直營。而在某些情況下,我們也會開始在大型市場考慮一些在地化製造,這對其中一些市場而言正變得愈來愈重要。

  • I think the final thing I'd say is we have ambitions internationally, just given we're earlier in penetration. And over time, there may be additional markets that we franchise with the distributors that we don't do business in today.

    我想最後要說的是,鑑於我們在國際市場的滲透率仍較早期,我們在國際上有企圖心。隨著時間推進,可能也會有更多我們目前尚未經營的市場,透過經銷商授權(franchise)來拓展。

  • David Rosa - Chief Executive Officer, Director

    David Rosa - Chief Executive Officer, Director

  • Okay. That was our last question. Thank you for all the questions. In closing, we continue to believe there's a substantial and durable opportunity to fundamentally improve surgery and acute interventions. Our teams continue to work closely with hospitals, physicians and care teams in pursuit of what our customers have termed at Quintuple Aim, better and more predictable patient outcomes, better experiences for patients, better experiences for their care teams, lower total cost of care; and finally, increased access to care.

    好的。那是我們最後一個問題。謝謝大家的提問。最後,我們仍然相信,在根本上改善外科手術與急性介入治療方面,存在龐大且可持續的機會。我們的團隊持續與醫院、醫師與照護團隊緊密合作,追求我們客戶所稱的「五重目標(Quintuple Aim)」:更好且更可預測的病患結果、更好的病患體驗、更好的照護團隊體驗、更低的整體照護成本;以及最後,提高照護可近性。

  • We believe value creation in surgery and acute care is foundationally human. It flows from respect for and understanding of patients and care teams and their needs and their environment. At Intuitive, we envision a future of care that is less invasive and profoundly better where diseases are identified earlier and treated quickly so patients can get back to what matters most.

    我們相信,在外科與急性照護中的價值創造,其根本是以人為本。它源自對病患與照護團隊的尊重與理解,以及對其需求與所處環境的理解。在Intuitive,我們描繪的未來照護將更微創且顯著更好;疾病能更早被辨識並迅速治療,讓病患能回到最重要的事。

  • Thank you for your support on this extraordinary journey. We look forward to talking with you again in three months.

    感謝你在這段非凡旅程中的支持。我們期待三個月後再次與你交流。

  • Operator

    Operator

  • This concludes today's conference call. Thank you for participating, and you may now disconnect. Everyone, have a great day.

    今天的電話會議到此結束。感謝各位參與,現在可以掛線。各位,祝你們今天愉快。